Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma. Background: While PTCL is treated for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback